Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501) Ended

2024-513492-41-00 Advanced solid tumors 3 2024-11-19
Study of JDQ443 in advanced cancer with a specific mutation (G12C) of the KRAS gene Ended

2023-508073-87-00 Advance solid tumors harboring the KRAS G12C mutation 7 2024-11-14
Prevention of cardiac Dysfunction during Adjuvant breast cancer therapy: A Randomized, Placebo-controlled, Multicenter Trial (PRADA-II) Ended

2024-515323-11-00 Heart Failure 4 2024-11-13
Sasanlimab Treatment As Bladder-Sparing Strategy For Patients With Muscle Invasive Bladder Cancer Ended

2024-511358-36-00 Molecularly Categorized Muscle Invasive Bladder Cancer 4 2024-11-11
Clinical Trial to compare subcutaneous pembrolizumab given with hyaluronidase to intravenous pembrolizumab in patients with newly diagnosed … Ended

2024-513165-39-00 Participants With Metastatic Non-small Cell Lung Cancer 5 2024-11-11
PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first… Ended

2024-518553-41-00 colon cancer and rectal with liver metastasis 5 2024-11-08
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Breast Cancer 5 2024-11-07
Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemo+immunotherapy in resectable e… Ended

2023-509584-24-01 Malignant Pleural Mesothelioma 4 2024-11-06
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec… Ended

2023-505617-24-00 Recurrent Ovarian Cancer with High Folate Receptor-Alph 4 2024-11-05
A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab tr… Ended

2024-513160-25-00 Melanoma and Non-small-cell lung cancer 5 2024-10-30
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Ref… Ended

2024-516149-38-00 Hodgkin Lymphoma 4 2024-10-29
Phase I trial with 177Lu-DOTA-TATE and olaparib in somatostatin receptor positive tumours Ended

2024-512463-31-00 Somatostatin receptor positive tumours 3 2024-10-27
Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients Ended

2023-509765-20-00 Melanoma: Adjuvant treatment of patients with Stage IIB 2 2024-10-21
PRODIGE 33 - BALLAD - Phase III study to evaluate the benefit of adjuvant chemotherapy in small bowel adenocarcinoma. Ended

2024-515299-11-00 SMALL BOWEL ADENOCARCINOMA 5 2024-10-18
Phase I trial of the new drug PhOx430 (inhibitor of the enzyme glucosaminyltransferase V) in patients with advanced solid tumors; first test… Ended

2024-516574-30-00 Adult patients with advanced or metastatic solid malign 1 2024-10-15
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastat… Ended

2023-509867-26-00 Advanced/metastatic solid tumor 1 2024-10-14
The p53 breast cancer trial Ended

2024-515135-29-00 breast cancer 4 2024-10-12
A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladde… Ended

2023-509460-19-00 Muscle Invasive bladder cancer 9 2024-10-11
A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment… Ended

2024-515936-62-00 Patients with advanced or metastatic gastrointestinal ( 9 2024-10-10
Randomized and multicentre Phase II study of FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) alone or in combination with hepatic chemoe… Ended

2024-517782-16-00 Colorectal cancer and metastatic disease limited to the 4 2024-10-10
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended

2024-512676-36-00 Langerhans Cell Histiocytosis 10 2024-10-09
A Phase 3 Single-arm Study of UGN-103 for the Treatment of LG IR NMIBC. Ended

2023-507261-25-00 Nonmuscle Invasive Bladder Cancer 5 2024-10-03
A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep… Ended

2023-506717-21-00 Breast Cancer 9 2024-10-02
Study of the impact of DPD activity on the efficacy of capecitabine Ended

2024-517481-41-00 breast cancer 9 2024-10-02